Lawsuits Filed Against BMRN, BIIB and YY - Jakubowitz Law Pursues Shareholders Claims

NEW YORK, NY / ACCESSWIRE / November 24, 2020 /Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

CONTACT JAKUBOWITZ ABOUT BMRN:
https://claimyourloss.com/securities/biomarin-pharmaceutical-inc-loss-submission-form/?id=11170&from=1

Class Period : February 28, 2020 - August 18, 2020

Lead Plaintiff Deadline: November 24, 2020

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) differences between the Phase 1/2 and Phase 3 study of valoctocogene roxaparvovec, an investigational adenoassociated virus gene therapy, limited the reliability of the Phase 1/2 study to support valoctocogene roxaparvovec's durability of effect; (ii) as a result, it was foreseeable that the U.S. Food and Drug Administration would not approve the Biologics License Application for valoctocogene roxaparvovec without additional data; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Biogen Inc. (NASDAQ:BIIB)

CONTACT JAKUBOWITZ ABOUT BIIB:
https://claimyourloss.com/securities/biogen-inc-loss-submission-form/?id=11170&from=1

Class Period : October 22, 2019 - November 6, 2019

Lead Plaintiff Deadline: January 12, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the larger dataset did not provide necessary data regarding aducanumab's effectiveness; (2) the EMERGE study did not and would not provide necessary data regarding the effectiveness of aducanumab, Biogen's investigational human monoclonal antibody studied for the treatment of early Alzheimer's disease; (3) the PRIME study did not and would not provide necessary data regarding aducanumab's effectiveness; (4) the data provided by the Company to the U.S. Food and Drug Administration's Peripheral and Central Nervous System Drugs Advisory Committee did not support finding efficacy of aducanumab; and (5) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Joyy Inc. (NASDAQ:YY)

CONTACT JAKUBOWITZ ABOUT YY:
https://claimyourloss.com/securities/joyy-inc-loss-submission-form/?id=11170&from=1

Class Period : April 28, 2016 - November 18, 2020

Lead Plaintiff Deadline: January 19, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) JOYY dramatically overstated its revenues from live streaming sources; (2) The majority of users at any given time were bots; (2) the Company utilized these bots to effect a roundtripping scheme that Manufactured the false appearance of revenues; (3) the Company overstated its cash reserves; (4) the Company's acquisition of Bigo was largely contrived to benefit corporate insiders; and (5) as a result, Defendants' public statements were materially false and/or Misleading at all relevant times.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

SOURCE:Jakubowitz Law

View source version on accesswire.com:
https://www.accesswire.com/618205/Lawsuits-Filed-Against-BMRN-BIIB-and-YY--Jakubowitz-Law-Pursues-Shareholders-Claims

© 2020 Accesswire. All Rights Reserved.